Naftidrofuryl oxalate
(Synonyms: 草酸萘呋胺; Nafronyl oxalate salt) 目录号 : GC61108
Naftidrofuryloxalate(Nafronyloxalatesalt)是在外周血和脑血管病症如血管扩张药的管理中使用的药物,增加细胞氧化能力,且是一种5-HT2受体拮抗剂。
Cas No.:3200-06-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Naftidrofuryl oxalate (Nafronyl oxalate salt) is a drug used in the management of peripheral and cerebral vascular disorders as a vasodilator, enhance cellular oxidative capacity, and may also be a 5-HT2 receptor antagonist.
Naftidrofuryl oxalate (Nafronyl oxalate salt) may be effective for relieving the pain of muscle cramps[1].Naftidrofuryl oxalate (Nafronyl oxalate salt) is the only vasoactive drug for peripheral arterial disease (PAD) which is likely to be cost-effective[2].Naftidrofuryl oxalate (Nafronyl oxalate salt) is ranked first for both maximum walking distance (MWD) and pain-free walking distance (PFWD) (probability of 0.947 and 0.987, respectively, of being the best treatment) followed by cilostazol and pentoxifylline. Naftidrofuryl oxalate (Nafronyl oxalate salt) is effective treatments for claudication, Naftidrofuryl oxalate is likely to be the most effective, with minimal serious adverse events[3].
[1]. Naftidrofuryl [2]. Meng Y, et al. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. Angiology. 2014 Mar;65(3):190-197. [3]. Stevens JW, et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012 Dec;99(12):1630-1638.
| Cas No. | 3200-06-4 | SDF | |
| 别名 | 草酸萘呋胺; Nafronyl oxalate salt | ||
| Canonical SMILES | O=C(OCCN(CC)CC)C(CC1=C2C=CC=CC2=CC=C1)CC3OCCC3.O=C(O)C(O)=O | ||
| 分子式 | C26H35NO7 | 分子量 | 473.56 |
| 溶解度 | DMSO: ≥ 100 mg/mL (211.17 mM); Water: 100 mg/mL (211.17 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1117 mL | 10.5583 mL | 21.1166 mL |
| 5 mM | 0.4223 mL | 2.1117 mL | 4.2233 mL |
| 10 mM | 0.2112 mL | 1.0558 mL | 2.1117 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet